State of New Jersey Common Pension Fund D lifted its stake in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 1.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,357 shares of the health services provider’s stock after purchasing an additional 339 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.06% of Amedisys worth $1,965,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently added to or reduced their stakes in AMED. Crossmark Global Holdings Inc. acquired a new stake in shares of Amedisys in the third quarter worth $243,000. State of Alaska Department of Revenue increased its stake in shares of Amedisys by 7.2% in the third quarter. State of Alaska Department of Revenue now owns 3,782 shares of the health services provider’s stock valued at $365,000 after buying an additional 255 shares in the last quarter. Signaturefd LLC increased its stake in shares of Amedisys by 20.9% in the third quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock valued at $132,000 after buying an additional 236 shares in the last quarter. Creative Planning increased its position in Amedisys by 12.6% in the third quarter. Creative Planning now owns 4,838 shares of the health services provider’s stock worth $467,000 after purchasing an additional 543 shares during the period. Finally, Exchange Traded Concepts LLC grew its position in shares of Amedisys by 6.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 7,508 shares of the health services provider’s stock worth $725,000 after buying an additional 450 shares during the period. Institutional investors and hedge funds own 94.36% of the company’s stock.
Amedisys Trading Down 0.3 %
NASDAQ AMED opened at $90.05 on Monday. Amedisys, Inc. has a fifty-two week low of $89.55 and a fifty-two week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock has a 50 day simple moving average of $96.04 and a two-hundred day simple moving average of $95.86. The stock has a market cap of $2.95 billion, a P/E ratio of 35.73, a price-to-earnings-growth ratio of 1.87 and a beta of 0.78.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on AMED. Deutsche Bank Aktiengesellschaft cut Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective on the stock. in a report on Monday, July 29th. Cantor Fitzgerald reiterated a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a research report on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $100.67.
View Our Latest Report on Amedisys
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Articles
- Five stocks we like better than Amedisys
- Most Volatile Stocks, What Investors Need to Know
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Following Congress Stock Trades
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- The 3 Best Retail Stocks to Shop for in August
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.